Sarah Tsuruo, Jamie Schlacter, Sanket S Dhruva, Joseph S Ross, Leora I Horwitz
{"title":"与医疗保险新技术附加支付计划相关的服务和支付。","authors":"Sarah Tsuruo, Jamie Schlacter, Sanket S Dhruva, Joseph S Ross, Leora I Horwitz","doi":"10.1093/haschl/qxae182","DOIUrl":null,"url":null,"abstract":"<p><p>In 2001, the Centers for Medicare and Medicaid Services established the New Technology Add-On Payment (NTAP) program to incentivize access to costly new technologies for Medicare beneficiaries. These technologies, authorized by the Food and Drug Administration (FDA), must demonstrate \"substantial clinical improvement\" when compared to existing technologies. However, in FY2021, the FDA introduced two expedited authorization pathways, allowing technologies with either designation to bypass the \"substantial clinical improvement\" criterion. We describe the services and payments associated with NTAPs following this policy change.</p>","PeriodicalId":94025,"journal":{"name":"Health affairs scholar","volume":"3 1","pages":"qxae182"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736715/pdf/","citationCount":"0","resultStr":"{\"title\":\"Services and payments associated with the medicare new technology add-on payment program.\",\"authors\":\"Sarah Tsuruo, Jamie Schlacter, Sanket S Dhruva, Joseph S Ross, Leora I Horwitz\",\"doi\":\"10.1093/haschl/qxae182\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In 2001, the Centers for Medicare and Medicaid Services established the New Technology Add-On Payment (NTAP) program to incentivize access to costly new technologies for Medicare beneficiaries. These technologies, authorized by the Food and Drug Administration (FDA), must demonstrate \\\"substantial clinical improvement\\\" when compared to existing technologies. However, in FY2021, the FDA introduced two expedited authorization pathways, allowing technologies with either designation to bypass the \\\"substantial clinical improvement\\\" criterion. We describe the services and payments associated with NTAPs following this policy change.</p>\",\"PeriodicalId\":94025,\"journal\":{\"name\":\"Health affairs scholar\",\"volume\":\"3 1\",\"pages\":\"qxae182\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736715/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health affairs scholar\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/haschl/qxae182\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health affairs scholar","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/haschl/qxae182","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Services and payments associated with the medicare new technology add-on payment program.
In 2001, the Centers for Medicare and Medicaid Services established the New Technology Add-On Payment (NTAP) program to incentivize access to costly new technologies for Medicare beneficiaries. These technologies, authorized by the Food and Drug Administration (FDA), must demonstrate "substantial clinical improvement" when compared to existing technologies. However, in FY2021, the FDA introduced two expedited authorization pathways, allowing technologies with either designation to bypass the "substantial clinical improvement" criterion. We describe the services and payments associated with NTAPs following this policy change.